The week in industry: AstraZeneca announces three, global-medicine R&D initiatives in China
This week: Sandoz (Holzkirchen, Germany) receives US FDA approval for its febrile neutropenia-induced infection treatment, Biogen (MA, USA) seeks to expand its biosimilar portfolio and an international collaboration aims to develop DNA damage response inhibitors.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>